Aclaris Therapeutics (ACRS) Phase 2 Trial Misses All Endpoints

Aclaris Therapeutics (ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug for atopic dermatitis missed all primary and secondary endpoints. The drug was well tolerated, but the company will focus on other pipeline assets, with upcoming catalysts including an IND filing for ATI-9494 and Phase 2b trials for modzatinib and ATI-052.

Original reporting
Published Nov 16, 2026, 8:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 8:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aclaris Therapeutics (ACRS) Phase 2 Trial Misses All Endpoints — source image
Decision brief

The 30-second read

$ACRSBearishMed
01

Why it matters

The miss could trigger a short‑term price decline and increase volatility, but the company's broader pipeline may sustain longer‑term valuation.

02

Market read

The trial failure is a material event for ACRS and may influence sentiment in the biotech sector.

03

What to watch

Potential for the company to pivot to other pipeline assets could mitigate long‑term impact.

Relevance 8/10Novelty 8/10Timing: today

Background

Aclaris Therapeutics focuses on dermatology and oncology drug development; the ADMIRATION trial was a key study for its atopic dermatitis candidate bosakitug.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Aclaris Therapeutics reported its Phase 2 ADMIRATION trial missed all primary and secondary endpoints.

Expected impact

downward pressure as the market prices in the trial failure

Evidence & confidence

Phase 2 miss is material biotech news; investors typically react with sell orders on such setbacks.

Market effects

May weigh on other dermatology biotech peers as investors reconsider pipeline risks.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond biotech investors.

Counterpoint

Some investors may view the miss as a buying opportunity if they believe the drug can still succeed in later trials.

Key entities

  • Aclaris Therapeutics

    Biopharma developing treatments for dermatology and oncology.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.